Why Is Dr. Reddy’s Laboratories Share Price Falling? Key Reasons & Share Price Target 2026

Thu Apr 16 2026

Dr. Reddy’s Laboratories (NSE: DRREDDY) share price is down –22% from 52W high — falling from a 52-week high of ₹1,420 to trade near ₹1,100 as of April 2026. For a company in the Pharmaceuticals / US Generics / CDMO sector with a market cap of ₹91,000 Cr, the decline has raised genuine investor questions: is this a buying opportunity, or is there a structural problem underneath the surface? This article examines every key reason behind the Dr. Reddy’s Laboratories share price falling, provides financial performance analysis, assesses institutional positioning, and offers a realistic share price target outlook for 2026.

Click Here – Get Free Investment Predictions on Univest

Share Price Snapshot — April 2026

Parameter	Value
Current Market Price (CMP)	₹1,100
52-Week High	₹1,420
52-Week Low	₹980
Decline from 52W High	–22% from 52W high
Market Capitalisation	₹91,000 Cr
Trailing P/E	18x
Promoter Holding	26.7%
FII Holding	30.2%
DII Holding	22.8%

Track live Dr. Reddy’s Laboratories fundamentals and analyst ratings on the Univest Screener.

5 Key Reasons Behind Dr. Reddy’s Laboratories Share Price Falling

Tap to Access Best Research Pieces on Univest

1. Revlimid Generic — Revenue Cliff as Exclusivity Ends

Dr. Reddy’s licensed generic of Lenalidomide (Revlimid — BMS’s blockbuster cancer drug) generated approximately $400–500 million annually during the exclusivity period (FY23–FY25). As additional generic competitors enter the market under the Bristol-Myers Squibb settlement, Dr. Reddy’s Revlimid revenue is declining rapidly — falling from a peak contribution of 15% of total revenue to an estimated 5% by FY27.

This revenue cliff is one of the most significant single-product revenue declines in Dr. Reddy’s recent history. The company must fill this gap with new US launches, CDMO growth, and India branded generics momentum — all of which are growing but not yet compensating at the same absolute revenue quantum.

2. US Generic Pricing — Structural Erosion

The US generics market has been experiencing 6–8% annual price erosion for the past 5 years — driven by Group Purchasing Organisation (GPO) consolidation forcing price-down negotiations, excess API (Active Pharmaceutical Ingredient) supply from India and China, and increased generic approvals by the US FDA creating competitive pressure.

Dr. Reddy’s US generics business — approximately 40% of total revenue — faces this structural headwind. Even when the company launches new molecules (which it does consistently with 15–20 US launches annually), existing portfolio price erosion offsets the new launch revenue in many quarters.

3. FDA Regulatory Risk — Manufacturing Site Observations

Dr. Reddy’s has historically faced FDA observations at its manufacturing sites — a standard challenge for Indian generic pharma companies with large API and formulation manufacturing footprints. Any FDA Warning Letter or Import Alert on a key manufacturing site can temporarily block US drug shipments from that facility — creating revenue gaps of ₹400–600 crore per quarter per blocked site.

While no specific FDA action is current as of April 2026, the sector-wide risk perception around India’s pharmaceutical manufacturing compliance keeps a permanent discount in Indian pharma stock valuations — including Dr. Reddy’s.

4. India Branded Generics — Competition Intensifying

Dr. Reddy’s India business (approximately 20% of total revenue) competes with Sun Pharma, Cipla, Alkem, and Abbott India in branded generic therapeutics. While the India business has been growing at 10–12%, competition from local branded players and the government’s push for generic drug dispensing (Jan Aushadhi) creates price pressure on branded generic business long-term.

The ‘India growth story’ has lower margins than the US business — limiting its ability to fully offset US revenue pressures.

5. US Tariff — Pharmaceutical Import Duty Risk

The US administration’s 26% tariff on Indian goods — with a potential carve-out under review for pharmaceuticals — creates investor uncertainty for Indian pharma companies. If pharmaceutical imports from India are subject to tariff, Dr. Reddy’s US business economics would be materially impacted (gross margins could fall 5–8 percentage points, requiring either price increases or margin acceptance).

While pharma tariffs are widely expected to be exempted given the US healthcare system’s dependence on Indian generics, the uncertainty is enough to compress Indian pharma stock PE multiples during the tariff debate period.

Dr. Reddy’s Laboratories — Recent News Timeline

April 2026: US tariff announcement on Indian goods creates sector-wide pharma selloff — Indian pharma companies down 3–6%.

March 2026: Dr. Reddy’s Q3 FY26: Revenue ₹8,021 Cr (+11% YoY) but Revlimid contribution falling as expected — US non-Revlimid business growing 18% YoY.

February 2026: Two new ANDA approvals for complex generics — pipeline continues to deliver but insufficient to offset Revlimid gap in near term.

January 2026: FDA inspection at Bachupally API plant — inspection completed without 483 observations — positive regulatory news.

December 2025: Dr. Reddy’s acquires Nickel (a dermatology brand) in India — diversifying India branded portfolio into dermatology.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Technical Support and Resistance Levels

Dr. Reddy’s Laboratories is trading at ₹1,100 versus a 52-week range of ₹980 to ₹1,420. The short-term support zone is ₹1,150–1,250 — representing the near-term base from which any recovery needs to hold. The 200-day moving average is the medium-term trend indicator to watch. For live price and technical setup, use the Univest Screener

Dr. Reddy’s Laboratories Share Price Target 2026

Click Here – Get Free Investment Predictions on Univest

Short-Term Target (3–6 Months)

Short-term Dr. Reddy’s Laboratories share price target: ₹1,150–1,250. This range assumes the key headwinds identified above begin to stabilise — no additional negative catalysts — and the broader market maintains current levels.

12-Month Analyst Consensus Target

The analyst consensus 12-month Dr. Reddy’s Laboratories share price target is ₹1,300–1,550 — implying meaningful upside from the current ₹1,100 if the fundamental headwinds begin to resolve over FY27. MOFSL, YES Securities, Kotak Institutional, and Jefferies are among the brokerages providing coverage.

Long-Term Target (FY27–FY28 Horizon)

For long-term investors with a 2–3 year horizon, the Dr. Reddy’s Laboratories share price target is ₹1,800–2,000 — assuming the company resolves the near-term headwinds identified in this article and delivers FY27–28 earnings recovery. These are analyst scenario estimates, not guaranteed returns.

Scenario	Target	Key Assumption
Bull Case	₹1,800–2,000	Headwinds resolve; earnings recover; multiple expands
Base Case (Consensus)	₹1,300–1,550	In-line FY27 delivery; stable valuation multiple
Bear Case	₹980 zone	Headwinds persist; FY27 earnings cut; multiple compresses

Subscribe to Univest Pro for premium research on Dr. Reddy’s Laboratories — Check Univest Screener

Conclusion — Is This a Buying Opportunity?

Dr. Reddy’s Laboratories share price is falling because of revlimid generic — revenue cliff as exclusivity ends — the primary catalyst — along with four additional headwinds detailed above. The 12-month analyst consensus target of ₹1,300–1,550 implies meaningful upside if these headwinds begin to resolve. Short-term support is at ₹1,150–1,250. Investors considering entry should monitor the key catalysts mentioned in each reason section and set a stop-loss at the 52-week low of ₹980 to manage downside risk.

For more falling stock analysis and share price targets, visit Univest Blogs.

Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.

Frequently Asked Questions

Q: Why is Dr. Reddy’s share price falling?

Dr. Reddy’s share price is falling due to: Revlimid (Lenalidomide) generic revenue declining as exclusivity period ends and more competitors enter; structural US generics price erosion of 6–8% annually on existing portfolio; US tariff uncertainty (26% on Indian goods) creating investor concern about pharma import economics; FDA regulatory risk perception; and India business margin compression from generic competition.

Q: What is Dr. Reddy’s share price target 2026?

Analyst consensus 12-month target: ₹1,300–1,550, implying 18–41% upside from ₹1,100. Short-term support: ₹1,150–1,250. Long-term FY28 bull case (CDMO growth, new US launches scaling, biosimilars): ₹1,800–2,000.

Q: Is Dr. Reddy’s a buy at ₹1,100?

At 18x PE — below the 5-year average of 22x — Dr. Reddy’s is at a reasonable entry point for long-term pharma investors. The Revlimid cliff is a known, temporary headwind. If non-Revlimid US business continues growing 15%+ and CDMO ramps, FY27–28 earnings recovery should drive re-rating. Consult a SEBI-registered advisor.

Q: What is the Revlimid (Lenalidomide) impact on Dr. Reddy’s?

Revlimid generic contributed approximately $400–500 million annually at peak (FY23–25) — roughly 15% of Dr. Reddy’s total revenue. As more generic competitors entered the market in FY25–26, this contribution is declining to an estimated 5% of revenue by FY27. This ~₹2,500–3,000 crore annual revenue cliff must be offset by growth elsewhere.

Q: What is Dr. Reddy’s US business?

US business accounts for approximately 40% of Dr. Reddy’s total revenue — around ₹14,000–15,000 crore annually. The company has 120+ generic drug registrations with the US FDA, launches 15–20 new products annually, and is building a biosimilars and CDMO business for future growth diversification.

Q: What is Dr. Reddy’s 52-week high and low?

Dr. Reddy’s 52-week high: ₹1,420. 52-week low: ₹980. Current ₹1,100 is 22% below the peak and 12% above the 52-week low.